Compass
发表于 2025-3-23 13:01:32
Imatinib Mesylate,y well tolerated with a low incidence of severe side effects. The most common adverse events include mild to moderate edema, muscle cramps, diarrhea, nausea, skin rashes, and myelosuppression. Several mechanisms of resistance have been identified. Clonal evolution, amplification, or overexpression o
Exposition
发表于 2025-3-23 17:03:17
http://reply.papertrans.cn/87/8685/868497/868497_12.png
谦卑
发表于 2025-3-23 21:19:26
Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor,sion of the existing label. In comparison with the other approved TKIs, bosutinib harbors a distinct side effect profile with only very few cardiovascular and thromboembolic events and minimal long-term safety issues with most adverse events happening during the first months of treatment. On the oth
投票
发表于 2025-3-24 02:15:57
http://reply.papertrans.cn/87/8685/868497/868497_14.png
礼节
发表于 2025-3-24 05:23:02
http://reply.papertrans.cn/87/8685/868497/868497_15.png
有花
发表于 2025-3-24 08:21:03
http://reply.papertrans.cn/87/8685/868497/868497_16.png
爱得痛了
发表于 2025-3-24 10:51:27
Pomalidomide,easome inhibitors (PI: bortezomib, carfilzomib) or antibodies, like elotuzumab or daratumumab. Pomalidomide has also been assessed in AL amyloidosis, MPNs (myelofibrosis ), Waldenstrom’s macroglobulinemia, solid tumors (sarcoma, lung cancer), or HIV, and—for AL amyloidosis and MF—has already bee
讥讽
发表于 2025-3-24 18:49:34
http://reply.papertrans.cn/87/8685/868497/868497_18.png
progestogen
发表于 2025-3-24 20:09:39
Venetoclax: Targeting BCL2 in Hematological Cancers,stic reduction of the tumor bulk within a few hours after administration. Venetoclax was approved by the FDA and EMA in 2016 for patients with previously treated CLL with del(17p13) and patients failing B cell receptor signaling inhibitors (EMA only), on the basis of a single-arm phase II trial demo
小口啜饮
发表于 2025-3-25 00:07:19
Carfilzomib,oing studies confirmed a tolerable safety profile of CFZ, a significantly lower incidence of neuropathy compared to bortezomib (BTZ) and a slightly higher incidence of cardiotoxicity, which is closely observed and precautions taken to avoid them as best as possible. In July 2012, the US Food and Dru